Glenmede Trust’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $616K | Buy |
2,714
+8
| +0.3% | +$1.43K | ﹤0.01% | 913 |
|
|
2026
Q1 | $467K | Buy |
2,706
+73
| +3% | +$13.5K | ﹤0.01% | 992 |
|
|
2025
Q4 | $525K | Buy |
+2,633
| New | +$478K | ﹤0.01% | 926 |
|
|
2024
Q4 | – | Sell |
-1,210
| Closed | -$238K | – | 1396 |
|
|
2024
Q3 | $238K | Buy |
1,210
+105
| +10% | +$21.8K | ﹤0.01% | 1178 |
|
|
2024
Q2 | $228K | Buy |
1,105
+18
| +2% | +$4.08K | ﹤0.01% | 1147 |
|
|
2024
Q1 | $295K | Buy |
1,087
+49
| +5% | +$11.7K | ﹤0.01% | 1066 |
|
|
2023
Q4 | $245K | Buy |
+1,038
| New | +$204K | ﹤0.01% | 1091 |
|
|
2023
Q1 | – | Sell |
-956
| Closed | -$208K | – | 1299 |
|
|
2022
Q4 | $208K | Buy |
+956
| New | +$209K | ﹤0.01% | 1088 |
|
|
2022
Q2 | – | Sell |
-831
| Closed | -$235K | – | 1308 |
|
|
2022
Q1 | $235K | Buy |
831
+48
| +6% | +$14.8K | ﹤0.01% | 1100 |
|
|
2021
Q4 | $294K | Sell |
783
-511
| -39% | -$199K | ﹤0.01% | 1055 |
|
|
2021
Q3 | $532K | Buy |
1,294
+22
| +2% | +$9.14K | ﹤0.01% | 892 |
|
|
2021
Q2 | $470K | Buy |
1,272
+441
| +53% | +$147K | ﹤0.01% | 910 |
|
|
2021
Q1 | $240K | Sell |
831
-107
| -11% | -$29.7K | ﹤0.01% | 1030 |
|
|
2020
Q4 | $233K | Sell |
938
-16
| -2% | -$3.81K | ﹤0.01% | 1020 |
|
|
2020
Q3 | $215K | Sell |
954
-141
| -13% | -$29.3K | ﹤0.01% | 1007 |
|
|
2020
Q2 | $190K | Sell |
1,095
-111
| -9% | -$17.7K | ﹤0.01% | 1026 |
|
|
2020
Q1 | $184K | Hold |
1,206
| – | – | ﹤0.01% | 1218 |
|
|
2019
Q4 | $184K | Buy |
1,206
+952
| +375% | +$132K | ﹤0.01% | 1218 |
|
|
2019
Q3 | $33K | Sell |
254
-185
| -42% | -$24.8K | ﹤0.01% | 1839 |
|
|
2019
Q2 | $62K | Sell |
439
-180
| -29% | -$24.4K | ﹤0.01% | 1579 |
|
|
2019
Q1 | $89K | Buy |
619
+180
| +41% | +$23.6K | ﹤0.01% | 1449 |
|
|
2018
Q4 | $48K | Sell |
439
-13,517
| -97% | -$1.69M | ﹤0.01% | 1607 |
|
|
2018
Q3 | $1.88M | Sell |
13,956
-20,995
| -60% | -$2.59M | 0.01% | 654 |
|
|
2018
Q2 | $3.92M | Hold |
34,951
| – | – | 0.02% | 504 |
|
|
2018
Q1 | $3.82M | Hold |
34,951
| – | – | 0.02% | 536 |
|
|
2017
Q4 | $3.82M | Sell |
34,951
-17
| -0% | -$1.85K | 0.02% | 536 |
|
|
2017
Q3 | $3.78M | Sell |
34,968
-2,358
| -6% | -$242K | 0.02% | 529 |
|
|
2017
Q2 | $3.36M | Hold |
37,326
| – | – | 0.02% | 539 |
|
|
2017
Q1 | $3.36M | Sell |
37,326
-6,779
| -15% | -$576K | 0.02% | 539 |
|
|
2016
Q4 | $3.36M | Sell |
44,105
-15
| -0% | -$1.14K | 0.02% | 525 |
|
|
2016
Q3 | $3.68M | Hold |
44,120
| – | – | 0.02% | 515 |
|
|
2016
Q2 | $3.64M | Sell |
44,120
-1,679
| -4% | -$138K | 0.02% | 509 |
|
|
2016
Q1 | $3.48M | Buy |
45,799
+160
| +0.4% | +$11.8K | 0.02% | 498 |
|
|
2015
Q4 | $3.67M | Sell |
45,639
-75
| -0.2% | -$5.41K | 0.03% | 486 |
|
|
2015
Q3 | $2.9M | Buy |
45,714
+7,027
| +18% | +$505K | 0.02% | 513 |
|
|
2015
Q2 | $2.72M | Buy |
38,687
+3,925
| +11% | +$290K | 0.02% | 506 |
|
|
2015
Q1 | $2.75M | Buy |
34,762
+122
| +0.4% | +$9K | 0.02% | 529 |
|
|
2014
Q4 | $2.2M | Hold |
34,640
| – | – | 0.02% | 551 |
|
|
2014
Q3 | $2.07M | Buy |
34,640
+23,940
| +224% | +$1.37M | 0.02% | 548 |
|
|
2014
Q2 | $572K | Buy |
+10,700
| New | +$587K | 0.01% | 826 |
|
Other funds holding CRL
AI
Glenmede Trust's CRL Position: Q2 2026 in Review
Glenmede Trust increased its Charles River Laboratories (CRL) stake by 0.3% in Q2 2026, buying an estimated $1.43K and bringing the position to 2,714 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #913.
Glenmede Trust first reported a position in CRL in Q2 2014 and has held it in 40 quarters since. The position peaked at $3.92M in Q2 2018. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Glenmede Trust held 2,714 shares of Charles River Laboratories worth $616K as of Q2 2026.
- Glenmede Trust bought 8 Charles River Laboratories shares in Q2 2026, an estimated $1.43K.
- Charles River Laboratories made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #913 holding.
- Glenmede Trust first reported a position in Charles River Laboratories in Q2 2014 and has held it in 40 quarters since.
- Glenmede Trust's Charles River Laboratories position peaked at $3.92M in Q2 2018.
- 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.